APPH: Apontis Pharma AG - Summary | Jitta

Apontis Pharma AG

DEU:APPH

Notice
Stock data is unavailable or the company’s delisted.
Price
€11.00
Loss Chance
54.3%
2.81JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (32)
Recent Business Performance (17)
Financial Strength (38)
Return to Shareholders (2)
Competitive Advantage (29)
Jitta Signs
Cash Conversion CycleLess than 60 days
Recent IPOLess than 3 years
Revenue and EarningEarning loss detected in 2023
Operating MarginDeclined
Recent Business PerformanceEarning decline 760.41% in the last year
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
2.81
100.00%
4.52
82.89%
4.17
65.16%
2.81
100.00%
2.81
100.00%
COMPANY DESCRIPTION
Apontis Pharma AG engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prophylaxis, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. As of November 21, 2024, Apontis Pharma AG operates as a subsidiary of Zentiva AG.